» Articles » PMID: 29896301

Endogenous PH-responsive Nanoparticles with Programmable Size Changes for Targeted Tumor Therapy and Imaging Applications

Overview
Journal Theranostics
Date 2018 Jun 14
PMID 29896301
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

Nanotechnology-based antitumor drug delivery systems, known as nanocarriers, have demonstrated their efficacy in recent years. Typically, the size of the nanocarriers is around 100 nm. It is imperative to achieve an optimum size of these nanocarriers which must be designed uniquely for each type of delivery process. For pH-responsive nanocarriers with programmable size, changes in pH (~6.5 for tumor tissue, ~5.5 for endosomes, and ~5.0 for lysosomes) may serve as an endogenous stimulus improving the safety and therapeutic efficacy of antitumor drugs. This review focuses on current advanced pH-responsive nanocarriers with programmable size changes for anticancer drug delivery. In particular, pH-responsive mechanisms for nanocarrier retention at tumor sites, size reduction for penetrating into tumor parenchyma, escaping from endo/lysosomes, and swelling or disassembly for drug release will be highlighted. Additional trends and challenges of employing these nanocarriers in future clinical applications are also addressed.

Citing Articles

Delving Into Nanoparticle Systems for Enhanced Drug Delivery Technologies.

Abaidullah N, Muhammad K, Waheed Y AAPS PharmSciTech. 2025; 26(3):74.

PMID: 40038143 DOI: 10.1208/s12249-025-03063-1.


Silica Nanoparticles: A Promising Vehicle for Anti-Cancer Drugs Delivery.

Aparna T, Kumar R, Ali S, Patel D, Julekha K, Begum T AAPS PharmSciTech. 2025; 26(1):33.

PMID: 39806209 DOI: 10.1208/s12249-024-02982-9.


Machine Learning-Driven Prediction, Preparation, and Evaluation of Functional Nanomedicines Via Drug-Drug Self-Assembly.

Zhang C, Yuan Y, Xia Q, Wang J, Xu K, Gong Z Adv Sci (Weinh). 2025; 12(9):e2415902.

PMID: 39792782 PMC: 11884566. DOI: 10.1002/advs.202415902.


Integrin-Specific Stimuli-Responsive Nanomaterials for Cancer Theranostics.

Taheri Z, Mozafari N, Moradian G, Lovison D, Dehshahri A, De Marco R Pharmaceutics. 2024; 16(11).

PMID: 39598564 PMC: 11597626. DOI: 10.3390/pharmaceutics16111441.


Concomitant Delivery of Pirarubicin and Salinomycin Synergistically Enhanced the Efficacy of Cancer Therapy and Reduced the Risk of Cancer Relapse.

Anees M, Gupta P, Kaur H, Kharbanda S, Singh H AAPS PharmSciTech. 2024; 25(7):211.

PMID: 39242397 DOI: 10.1208/s12249-024-02918-3.


References
1.
Wilson J, Keller S, Manganiello M, Cheng C, Lee C, Opara C . pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides. ACS Nano. 2013; 7(5):3912-25. PMC: 4042837. DOI: 10.1021/nn305466z. View

2.
Huang X, Brazel C . On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J Control Release. 2001; 73(2-3):121-36. DOI: 10.1016/s0168-3659(01)00248-6. View

3.
Li Y, Zhao T, Wang C, Lin Z, Huang G, Sumer B . Molecular basis of cooperativity in pH-triggered supramolecular self-assembly. Nat Commun. 2016; 7:13214. PMC: 5095283. DOI: 10.1038/ncomms13214. View

4.
King M, Mohamed Z . Dual nanoparticle drug delivery: the future of anticancer therapies?. Nanomedicine (Lond). 2016; 12(2):95-98. DOI: 10.2217/nnm-2016-0378. View

5.
Meng F, Zhong Y, Cheng R, Deng C, Zhong Z . pH-sensitive polymeric nanoparticles for tumor-targeting doxorubicin delivery: concept and recent advances. Nanomedicine (Lond). 2014; 9(3):487-99. DOI: 10.2217/nnm.13.212. View